Envestnet Asset Management
PVLA

Envestnet Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Envestnet Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$308K Buy
2,017
+164
+9% +$19.9K ﹤0.01% 4410
2026
Q1 		$231K Buy
+1,853
New +$193K ﹤0.01% 4432

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Envestnet Asset Management's PVLA Position: Q2 2026 in Review

Envestnet Asset Management increased its Palvella Therapeutics (PVLA) stake by 8.9% in Q2 2026, buying an estimated $19.9K and bringing the position to 2,017 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #4410.

Envestnet Asset Management first reported a position in PVLA in Q1 2026 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Envestnet Asset Management held 2,017 shares of Palvella Therapeutics worth $308K as of Q2 2026.
  • Envestnet Asset Management bought 164 Palvella Therapeutics shares in Q2 2026, an estimated $19.9K.
  • Palvella Therapeutics made up ﹤0.01% of Envestnet Asset Management's portfolio in Q2 2026, its #4410 holding.
  • Envestnet Asset Management first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Envestnet Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.